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Abstract
Background
There is disagreement about the level of asymptomatic severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We conducted a living systematic review and meta-
analysis to address three questions: (1) Amongst people who become infected with SARS-
CoV-2, what proportion does not experience symptoms at all during their infection? (2)
Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed,
what proportion will develop symptoms later? (3) What proportion of SARS-CoV-2 transmis-
sion is accounted for by people who are either asymptomatic throughout infection or
presymptomatic?
Methods and findings
We searched PubMed, Embase, bioRxiv, and medRxiv using a database of SARS-CoV-2
literature that is updated daily, on 25 March 2020, 20 April 2020, and 10 June 2020. Studies
of people with SARS-CoV-2 diagnosed by reverse transcriptase PCR (RT-PCR) that docu-
mented follow-up and symptom status at the beginning and end of follow-up or modelling
studies were included. One reviewer extracted data and a second verified the extraction,
with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical stud-
ies was assessed with an adapted checklist for case series, and the relevance and credibility
of modelling studies were assessed using a published checklist. We included a total of 94
studies. The overall estimate of the proportion of people who become infected with SARS-
CoV-2 and remain asymptomatic throughout infection was 20% (95% confidence interval
[CI] 17–25) with a prediction interval of 3%–67% in 79 studies that addressed this review
question. There was some evidence that biases in the selection of participants influence the
estimate. In seven studies of defined populations screened for SARS-CoV-2 and then
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followed, 31% (95% CI 26%–37%, prediction interval 24%–38%) remained asymptomatic.
The proportion of people that is presymptomatic could not be summarised, owing to hetero-
geneity. The secondary attack rate was lower in contacts of people with asymptomatic infec-
tion than those with symptomatic infection (relative risk 0.35, 95% CI 0.10–1.27). Modelling
studies fit to data found a higher proportion of all SARS-CoV-2 infections resulting from
transmission from presymptomatic individuals than from asymptomatic individuals. Limita-
tions of the review include that most included studies were not designed to estimate the pro-
portion of asymptomatic SARS-CoV-2 infections and were at risk of selection biases; we did
not consider the possible impact of false negative RT-PCR results, which would underesti-
mate the proportion of asymptomatic infections; and the database does not include all
sources.
Conclusions
The findings of this living systematic review suggest that most people who become infected
with SARS-CoV-2 will not remain asymptomatic throughout the course of the infection. The
contribution of presymptomatic and asymptomatic infections to overall SARS-CoV-2 trans-
mission means that combination prevention measures, with enhanced hand hygiene, masks,
testing tracing, and isolation strategies and social distancing, will continue to be needed.
Author summary
Why was this study done?
• The proportion of people who will remain asymptomatic throughout the course of
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
cause of coronavirus disease 2019 (COVID-19), is not known.
• Studies that assess people at just one time point will overestimate the proportion of true
asymptomatic infection because those who go on to develop COVID-19 symptoms will
be wrongly classified as asymptomatic rather than presymptomatic.
• The amount, and infectiousness, of asymptomatic SARS-CoV-2 infection will determine
what kind of measures will prevent transmission most effectively.
What did the researchers do and find?
• We did a living systematic review through 10 June 2020, using automated workflows
that speed up the review processes and allow the review to be updated when relevant
new evidence becomes available.
• Overall, in 79 studies in a range of different settings, 20% (95% confidence interval [CI]
17%–25%, prediction interval 3%–67%) of people with SARS-CoV-2 infection remained
asymptomatic during follow-up, but biases in study designs limit the certainty of this
estimate.
• In seven studies of defined populations screened for SARS-CoV-2 and then followed,
31% (95% CI 26%–37%, prediction interval 24%–38%) remained asymptomatic.
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• We found some evidence that SARS-CoV-2 infection in contacts of people with asymp-
tomatic infection is less likely than in contacts of people with symptomatic infection
(relative risk 0.35, 95% CI 0.10–1.27).
What do these findings mean?
• The findings of this living systematic review suggest that most people who become
infected with SARS-CoV-2 will not remain asymptomatic throughout the course of
infection.
• Future studies should be designed specifically to determine the true proportion of
asymptomatic SARS-CoV-2 infections, using methods to minimise biases in the selec-
tion of study participants and ascertainment of symptom status during follow-up.
• The contribution of presymptomatic and asymptomatic infections to overall SARS-
CoV-2 transmission means that combination prevention measures, with enhanced
hand hygiene, masks, testing tracing, and isolation strategies and social distancing, will
continue to be needed.
Introduction
There is ongoing discussion about the level of asymptomatic severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection. The authors of a narrative review report a
range of proportions of participants positive for SARS-CoV-2 but asymptomatic in different
studies from 6% to 96% [1]. The discrepancy results, in part, from the interpretation of studies
that report a proportion of asymptomatic people with SARS-CoV-2 detected at a single point.
The studies cited include both people who will remain asymptomatic throughout and those,
known as presymptomatic, who will develop symptoms of coronavirus disease 2019 (COVID-
19) if followed up [2]. The full spectrum and distribution of COVID-19, from completely
asymptomatic, to mild and nonspecific symptoms, viral pneumonia, respiratory distress syn-
drome, and death, are not yet known [3]. Without follow-up, however, the proportions of
asymptomatic and presymptomatic infections cannot be determined.
Accurate estimates of the proportions of true asymptomatic and presymptomatic infections
are needed urgently because their contribution to overall SARS-CoV-2 transmission at the
population level will determine the appropriate balance of control measures [3]. If the predom-
inant route of transmission is from people who have symptoms, then strategies should focus
on testing, followed by isolation of infected individuals and quarantine of their contacts. If,
however, most transmission is from people without symptoms, social distancing measures that
reduce contact with people who might be infectious should be prioritised, enhanced by active
case-finding through testing of asymptomatic people.
The objectives of this study were to address three questions: (1) Amongst people who
become infected with SARS-CoV-2, what proportion do not experience symptoms at all dur-
ing their infection? (2) Amongst people with SARS-CoV-2 infection who are asymptomatic
when diagnosed, what proportion will develop symptoms later? (3) What proportion of
SARS-CoV-2 transmission is accounted for by people who are either asymptomatic through-
out infection or presymptomatic?
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Methods
We conducted a living systematic review, a systematic review that provides an online summary
of findings and is updated when relevant new evidence becomes available [4]. The review fol-
lows a published protocol (https://osf.io/9ewys/), which describes in detail the methods used
to speed up review tasks [5] and to assess relevant evidence rapidly during a public health
emergency [6]. The first two versions of the review have been published as preprints [7,8]. We
report our findings according to the statement on preferred reporting items for systematic
reviews and meta-analyses (S1 PRISMA Checklist) [9]. Ethics committee review was not
required for this study. Box 1 shows our definitions of symptoms, asymptomatic infection, and
presymptomatic status. We use the term asymptomatic SARS-CoV-2 infection for people
without symptoms of COVID-19 who remain asymptomatic throughout the course of infec-
tion. We use the term presymptomatic for people who do not have symptoms of COVID-19
when enrolled in a study but who develop symptoms during adequate follow-up.
Information sources and search
We conducted the first search on 25 March 2020 and updated it on 20 April and 10 June 2020.
We searched the COVID-19 living evidence database [10], which is generated using automated
workflow processes [5] to (1) provide daily updates of searches of four electronic databases
(Medline PubMed, Ovid Embase, bioRxiv, and medRxiv), using medical subject headings and
free-text keywords for SARS-CoV-2 infection and COVID-19; (2) de-duplicate the records; (3)
tag records that are preprints; and (4) allow searches of titles and abstracts using Boolean oper-
ators. We used the search function to identify studies of asymptomatic or presymptomatic
SARS-CoV-2 infection using a search string of medical subject headings and free-text
Box 1. Definitions of symptoms and symptom status in a person with
SARS-CoV-2 infections
Symptoms: symptoms that a person experiences and reports. We used the authors’ defi-
nitions. We searched included manuscripts for an explicit statement that the study par-
ticipant did not report symptoms that they experienced. Some authors defined
‘asymptomatic’ as an absence of self-reported symptoms. We did not include clinical
signs observed or elicited on examination.
Asymptomatic infection: a person with laboratory-confirmed SARS-CoV-2 infection,
who has no symptoms, according to the authors’ report, at the time of first clinical
assessment and had no symptoms at the end of follow-up. The end of follow-up was
defined as any of the following: virological cure, with one or more negative reverse tran-
scriptase PCR (RT-PCR) test results; follow-up for 14 days or more after the last possible
exposure to an index case; follow-up for 7 days or more after the first RT-PCR positive
result.
Presymptomatic: a person with laboratory-confirmed SARS-CoV-2 infection, who has
no symptoms, according to the authors’ report, at the time of first clinical assessment
but who developed symptoms by the end of follow-up. The end of follow-up was defined
as any of the following: virological cure, with one or more negative RT-PCR test results;
follow-up for 14 days or more after the last possible exposure to an index case; follow-up
for 7 days or more after the first RT-PCR positive result.
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keywords (S1 Text). We also examined articles suggested by experts and the reference lists of
retrieved mathematical modelling studies and systematic reviews. Reports from this living
rapid systematic review will be updated at 3-monthly intervals, with continuously updated
searches.
Eligibility criteria
We included studies in any language of people with SARS-CoV-2 diagnosed by RT-PCR that
documented follow-up and symptom status at the beginning and end of follow-up or investi-
gated the contribution to SARS-CoV-2 transmission of asymptomatic or presymptomatic
infection. We included contact-tracing investigations, case series, cohort studies, case-control
studies, and statistical and mathematical modelling studies. We excluded the following study
types: case reports of a single patient and case series in which participants were not enrolled
consecutively. When multiple records included data from the same study population, we
linked the records and extracted data from the most complete report.
Study selection and data extraction
Reviewers worked in pairs to screen records using an application programming interface in
the electronic data capture system (REDCap, Vanderbilt University, Nashville, TN, USA). One
reviewer selected potentially eligible studies and a second reviewer verified all included and
excluded studies. We reported the identification, exclusion, and inclusion of studies in a flow-
chart (S1 Fig). The reviewers determined which of the three review questions each study
addressed, using the definitions in Box 1. One reviewer extracted data using a pre-piloted
extraction form in REDCap, and a second reviewer verified the extracted data using the query
system. A third reviewer adjudicated on disagreements that could not be resolved by discus-
sion. We contacted study authors for clarification when the study description was insufficient
to reach a decision on inclusion or if reported data in the manuscript were internally inconsis-
tent. The extracted variables included, but were not limited to, study design, country and/or
region, study setting, population, age, primary outcomes, and length of follow-up. From
empirical studies, we extracted raw numbers of individuals with any outcome and its relevant
denominator. From statistical and mathematical modelling studies, we extracted proportions
and uncertainty intervals reported by the authors.
The primary outcomes for each review question were (1) proportion with asymptomatic
SARS-CoV-2 infection who did not experience symptoms at all during follow-up; (2) propor-
tion with SARS-CoV-2 infections who did not have symptoms at the time of testing but devel-
oped symptoms during follow-up; (3) estimated proportion (with uncertainty interval) of
SARS-CoV-2 transmission accounted for by people who are asymptomatic or presymptom-
atic. A secondary outcome for review question 3 was the secondary attack rate from asymp-
tomatic or presymptomatic index cases.
Risk of bias in included studies
Two authors independently assessed the risk of bias. A third reviewer resolved disagreements.
For observational epidemiological studies, we adapted the Joanna Briggs Institute Critical
Appraisal Checklist for Case Series [11]. The adapted tool included items about inclusion crite-
ria, measurement of asymptomatic status, follow-up of course of disease, and statistical analy-
sis. We added items about selection biases affecting the study population from a tool for the
assessment of risk of bias in prevalence studies [12]. For mathematical modelling studies, we
used a checklist for assessing relevance and credibility [13].
PLOS MEDICINE Asymptomatic SARS-CoV-2 infection: Living systematic review
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003346 September 22, 2020 5 / 25
Synthesis of the evidence
We used the ‘metaprop’ and ‘metabin’ functions from the ‘meta’ package (version 4.11–0) [14]
in R (version 3.5.1) to display the study findings in forest plots and synthesise their findings.
The 95% confidence intervals (CIs) for each study are estimated using the Clopper-Pearson
method [15]. We examined heterogeneity visually in forest plots. We stratified studies accord-
ing to the methods used to identify people with asymptomatic SARS-CoV-2 infection and the
study setting. To synthesise proportions from comparable studies, in terms of design and pop-
ulation, we used stratified random-effects meta-analysis. For the stratified and overall sum-
mary estimates, we calculated prediction intervals, to represent the likely range of proportions
that would be obtained in subsequent studies conducted in similar settings [16]. We calculated
the secondary attack rate as the number of cases among contacts as a proportion of all close
contacts ascertained. We did not account for potential clustering of contacts because the
included studies did not report the size of clusters. We compared the secondary attack rate
from asymptomatic or presymptomatic index cases with that from symptomatic cases. If there
were no events in a group, we added 0.5 to each cell in the 2 × 2 table. We used random-effects
meta-analysis with the Mantel-Haenszel method to estimate a summary risk ratio (with 95%
CI).
Results
The living evidence database contained a total of 25,538 records about SARS-CoV-2 or
COVID-19 by 10 June 2020. The searches for studies about asymptomatic or presymptomatic
SARS-CoV-2 on 25 March, 20 April, and 10 June resulted in 89, 230, and 688 records for
screening (S1 Fig). In the first version of the review [7], 11 articles were eligible for inclusion
[17–27], version 2 [8] identified another 26 eligible records [28–53], and version 3 identified
another 61 eligible records [54–114]. After excluding four articles for which more recent data
became available in a subsequent version [25,29,30,35], the total number of articles included
was 94 (S1 Table) [17–24,26–28,31–34,36–114]. The types of evidence changed across the
three versions of the review (S1 Table). In the first version, six of 11 studies were contact inves-
tigations of single-family clusters with a total of 39 people. In the next versions, study designs
included larger investigations of contacts and outbreaks, screening of defined groups, and
studies of hospitalised adults and children. Across all three review versions, data from 79
empirical observational studies were collected in 19 countries or territories (Tables 1 and 2)
and included 6,832 people with SARS-CoV-2 infection. Forty-seven of the studies, including
3,802 infected people, were done in China (S2 Table). At the time of their inclusion in the
review, 23 of the included records were preprints; six of these had been published in peer-
reviewed journals by 17 July 2020 [19,20,27,81,82,106].
Proportion of people with asymptomatic SARS-CoV-2 infection
We included 79 studies that reported empirical data about 6,616 people with SARS-CoV-2
infection (1,287 defined as having asymptomatic infection) [17,18,21–23,26–28,31,32,34,36,
39–45,47–50,52–54,56–62,64,66–68,70–77,79–90,92–112,114] and one statistical modelling
study [24] (Table 1). The sex distribution of the people with asymptomatic infection was
reported in 41/79 studies, and the median age was reported in 35/79 studies (Table 1). The
results of the studies were heterogeneous (S2 Fig). We defined seven strata, according to the
method of selection of asymptomatic status and study settings. Study findings within some of
these strata were more consistent (Fig 1). We considered the statistical modelling study of pas-
sengers on the Diamond Princess cruise ship passengers [24] separately, because of the different
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Table 1. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections.
Author Country, location Total SARS-CoV-
2, n
Asymptomatic
SARS-CoV-2, n
Sex of asymptomatic
people
Age of asymptomatic people,
years, median
Follow-up
methoda
Contact investigation, single
Tong, ZD [44] China, Zhejiang 5 3 2 F, 3 M 28
IQR 12–41
1, 3
Huang, R [74] China, Suqian 2 1 1 F, 0 M 54 3
Jiang, XL [76] China, Shandong 8 3 3 F, 0 M 35
IQR 0–53
3
Jiang, X [75] China, Chongqing 3 1 1 F, 0 M 8 2
Liao, J [22] China, Chongqing 12 3 NR NR 1, 2
Hu, Z [21] China, Nanjing 4 1 0 F, 1 M 64 2, 3
Luo, SH [23] China, Anhui 4 1 1 F, 0 M 50 1, 2, 3
Chan, JF [18] China, Guangdong 5 1 0 F, 1 M 10 1
Ye, F [49] China, Sichuan 5 1 0 F, 1 M 28 1, 2
Bai, Y [17] China, Anyang 6 1 1 F, 0 M 20 1
Luo, Y [85] China, Wuhan 6 5 NR 37
IQR 7–62
1
Zhang, J [50] China, Wuhan and
Beijing
5 2 1 F, 1 M NR 2
Zhang, B [110] China, Guangdong 7 2 0 F, 2 M 13.5
IQR 13–14
3
Huang, L [73] China, Gansu 7 2 2 F, 0 M 44
IQR 38.5–49.5
2
Qian, G [26] China, Zhejiang 8 2 1 F, 1 M 30.5
IQR 1–60
1, 2
Gao, Y [70] China, Wuxi 15 6 3 F, 3 M 50
IQR 48–51
1, 2
Contact investigation, aggregated
Hijnen, D [72] Germany 11 1 0 F, 1 M 49 1
Brandstetter, S [62] Germany 36 2 NR NR 2
Zhang, W2 [111] China, Guiyang 12 4 NR NR 1, 2, 3
Cheng, HY [66] Taiwan 22 4 NR NR 1
Wang, Z [47] China, Wuhan 47 4 NR NR 1
Wu, J [105] China, Zhuhai 83 8 NR NR 1, 2
Luo, L [36] China, Guangzhou 129 8 NR NR 1, 2, 3
Bi, Q [60] China, Shenzhen 87 17 NR NR 2, 3
Yang, R [108] China, Wuhan 78 33 22 F, 11 M 37
IQR 26–45
3
Outbreak investigation
Danis, K [32] France 13 1 NR NR 1, 2
Böhmer, MM [61] Germany 16 1 NR NR 1
Roxby, AC [94] USA 6 3 NR NR 1
Yang, N [48] China, Xiaoshan 10 2 1 F, 1 M NR 1, 2
Schwierzeck, V [95] Germany 12 2 NR NR 2
Arons, MM [58] USA 47 3 NR NR 2
Park, SY [90] South Korea 97 4 NR NR 2
Dora, AV [68] USA 19 6 0 F, 6 M 75
IQR 72–75
3
Tian, S [43] China, Shandong 24 7 NR NR 3
Solbach, W [97] Germany 97 10 NR NR 2
Graham, N [71] United Kingdom 126 46 NR NR 2
(Continued)
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Table 1. (Continued)
Author Country, location Total SARS-CoV-
2, n
Asymptomatic
SARS-CoV-2, n
Sex of asymptomatic
people
Age of asymptomatic people,
years, median
Follow-up
methoda
Pham, TQ [100] Vietnam 208 89 NR 31
IQR 23–45
2
Screening of defined population
Hoehl, S [34] Germany 2 1 0 F, 1 M 58 2
Chang, L [31] China, Wuhan 4 2 0 F, 2 M 45
IQR 37–53
2
Arima, Y [28] Japan 12 4 NR NR 1, 2
Rivett, L [93] United Kingdom 30 5 NR NR 2
Treibel, TA [101] United Kingdom 44 12 NR NR 2
Lavezzo, E [81] Italy 73 29 NR NR 2
Lombardi, A [82] Italy 138 41 NR NR 3
Hospitalised adults
Pongpirul, WA [39] Thailand 11 1 1 F, 0 M 66 2, 3
Zou, L [53] China, Zhuhai 18 1 1 M, 0 M 26 1
Qiu, C [92] China, Hunan 104 5 NR NR 2
Zhou, R [114] China, Guangdong 31 9 NR NR 3
Chang, MC [64] South Korea 139 10 4 F, 6 M NR 1, 2
Zhou, X [52] China, Shanghai 328 10 NR NR 1, 2, 3
Angelo Vaira, L [57] Italy 345 10 NR NR 3
Wang, X [45] China, Wuhan 1012 14 NR NR 1, 2
Wong, J [103] Brunei 138 16 NR NR 2, 3
Xu, T [107] China, Jiangsu 342 15 5 F, 10 M 27
IQR 17–36
2, 3
London, V [83] USA 68 22 22 F, 0 M 30.5
IQR 24.5–34.8
2
Tabata, S [27] Japanb 104 33 18 F, 15 M 70
IQR 57–75
2
Andrikopoulou, M
[56]
USA 158 46 46 F, 0 M NR 1, 2
Noh, JY [89] South Korea 199 53 NR NR 3
Kumar, R [80] India, New Delhi 231 108 18 F, 90 M NR 2, 3
Hospitalised children
See, KC [41] Malaysia 4 1 0 F, 1 M 9 1, 2, 3
Tan, YP [42] China, Changsha 10 2 1 F, 1 M 8 2, 3
Tan, X [99] China, Changsha 13 2 2 F, 0 M 5
IQR 2–8
1, 2, 3
Melgosa, M [87] Spain 16 3 NR NR 1, 2
Wu, HP [104] China, Jiangxi 23 3 NR NR 3
Song, W [98] China, Hubei 16 8 3 F, 5 M 11
IQR 7–12
1, 2
Bai, K [59] China, Chongqing 25 8 NR NR 3
Xu, H [106] China, Guizhou 32 11 4 F, 7 M NR 1, 2
Qiu, H [40] China, Zhejiang 36 10 NR NR 1, 2, 3
Lu, Y [84] China, Wuhan 110 29 12 F, 17 M 7
IQR 6–11
2, 3
Hospitalised adults and children
Merza, MA [88] Iraqi Kurdistan 15 6 NR NR 2, 3
Yongchen, Z [109] China, Jiangsu 21 5 2 F, 3 M 25
IQR 14–54
1, 2, 3
(Continued)
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method of analysis and overlap with the study population reported by Tabata and colleagues
[27].
The main risks of bias across all categories of empirical studies were in the selection and
enrolment of people with asymptomatic infection and mismeasurement of asymptomatic sta-
tus because of absent or incomplete definitions (S3 Fig). Sources of bias specific to studies in
particular settings are discussed with the relevant results.
The overall estimate of the proportion of people who become infected with SARS-CoV-2
and remain asymptomatic throughout the course of infection was 20% (95% CI 17%–25%, 79
studies), with a prediction interval of 3%–67% (Fig 1). One statistical modelling study was
based on data from all 634 passengers from the Diamond Princess cruise ship with RT-PCR
positive test results [24]. The authors adjusted for the proportion of people who would develop
symptoms (right censoring) in a Bayesian framework to estimate that, if all were followed up
until the end of the incubation period, the probability of asymptomatic infections would be
17.9% (95% credibility interval [CrI] 15.5%–20.2%).
The summary estimates of the proportion of people with asymptomatic SARS-CoV-2 infec-
tion differed according to study setting, although prediction intervals for all groups over-
lapped. The first three strata in Fig 1 involve studies that reported on different types of contact
investigation, which start with an identified COVID-19 case. The studies reporting on single-
family clusters (21 estimates from 16 studies in China, n = 102 people with SARS-CoV-2) all
included at least one asymptomatic person [17,18,21–23,26,44,49,50,70,73–76,85,110]. The
summary estimate was 34% (95% CI 26%–44%, prediction interval 25%–45%). In nine studies
that reported on close contacts of infected individuals and aggregated data from clusters of
both asymptomatic and symptomatic people with SARS-CoV-2 the summary estimate was
14% (95% CI 8%–23%, prediction interval 2%–53%) [36,47,60,62,66,72,105,108,111]. We
included 12 studies (n = 675 people) that reported on outbreak investigations arising from a
single symptomatic person or from the country’s first imported cases of people with COVID-
19 [32,43,48,58,61,68,71,90,94,95,97,100]. Four of the outbreaks involved nursing homes
[58,68,71,94] and four involved occupational settings [43,61,90,95]. The summary estimate of
Table 1. (Continued)
Author Country, location Total SARS-CoV-
2, n
Asymptomatic
SARS-CoV-2, n
Sex of asymptomatic
people
Age of asymptomatic people,
years, median
Follow-up
methoda
Ma, Y [86] China, Shandong 47 11 5 F, 6 M 23
IQR NR
2
Kim, SE [77] South Korea 71 10 6 F, 4 M 31
IQR 21–55
2
Choe, PG [67] South Korea 113 15 17 F, 8 M NR 3
Sharma, AK [96] India, Jaipur 234 215 NR NR 1, 2, 3
Zhang, W3 [112] China, Guiyang 137 26 12 F, 14 M 24
IQR 12–36
1, 2
Alshami, AA [54] Saudi Arabia 128 69 36 F, 33 M NR 2, 3
Kong, W [79] China, Sichuan 473 45 NR NR 1, 2
Wang, Y2 [102] China, Chongqing 279 63 29 F, 34 M 39
IQR 27–53
3
aFollow-up according to protocol (1: 14 days after last possible exposure; 2: 7 days after diagnosis; 3: until negative RT-PCR result).
bPeople of different nationalities taken from Diamond Princess cruise ship to a hospital in Japan.
Abbreviations: F, female; IQR, interquartile range; M, male; NR, not reported; RT-PCR, reverse transcriptase PCR; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; USA, United States of America
https://doi.org/10.1371/journal.pmed.1003346.t001
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Table 2. Characteristics of studies that measured the proportion of people with SARS-CoV-2 infection that develops symptoms.
Author Country,
location
Total asymptomatic
SARS-CoV-2, n
Develop symptoms
after testing, n
Sex of asymptomatic
people at time of testing
Age of
asymptomatic people at time
of testing, years, median
Follow-up
methoda
Contact investigation, single
Ye, F [49] China, Sichuan 3 2 0 F, 3 M 28
IQR 23–50
1, 2
Zhang, B [110] China,
Guangdong
4 2 0 F, 4 M 34
IQR 33–35
3
Huang, L [73] China, Gansu 4 2 3 F, 1 M 44.5
IQR 34.50–54.25
2
Jiang, XL [76] China,
Shandong
5 2 3 F, 2 M 35
IQR 35–37
3
Hu, Z [21] China, Nanjing 24 5 NR NR 2, 3
Contact investigation, aggregated
Zhang, W2 [111] China,
Guangzhou
12 8 NR NR 1, 2, 3
Outbreak investigation
Schwierzeck, V
[95]
Germany 6 4 NR NR 2
Park, SY [90] South Korea 8 4 NR NR 2
Arons, MM [58] USA 27 24 NR NR 2
Dora, AV [68] USA 14 8 0 F, 14 M NR 3
Graham, N [71] United
Kingdom
54 8 NR NR 1
Screening of defined population
Hoehl, S [34] Germany 2 1 1 F, 1 M 51 2
Rivett, L [93] United
Kingdom
6 1 NR NR 2
Chang, L [31] China, Wuhan 4 2 1 F, 3 M 39.5
IQR 29–47.5
2
Arima, Y [28] Japan 5 2 NR NR 1, 2
Lytras, T [37] Greece 39 4 NR NR 2
Lavezzo, E [81] Italy 39 10 NR NR 2
Hospitalised adults
Al-Shamsi, HO
[55]
United Arab
Emirates
7 7 5 F, 2 M 51.6
IQR 40–76
3
Luo, SH [23] China, Anhui 8 7 NR NR 1, 2, 3
Zhou, X [52] China,
Shanghai
13 3 7 F, 6 M NR 2, 3
Zhou, R [114] China,
Guangdong
31 22 NR NR 3
Wang, X [45] China, Wuhan 30 16 NR NR 1, 2
Tabata, S [27] Cruise Ship 43 10 24 F, 19 M 69
IQR 60.5–75
2
Wang, Y1 [46] China,
Shenzhen
55 43 NR 49
IQR 2–69
3
Meng, H [38] China, Wuhan 58 16 NR NR 2
Andrikopoulou, M
[56]
USA 63 16 63 F, 0 M NR 1, 2
Zhang, Z [113] China,
Shenzhen
56 33 33 F, 23 M NR 2, 3
Wong, J [103] Brunei 138 42 NR NR 2, 3
Hospitalised children
(Continued)
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the proportion of asymptomatic SARS-CoV-2 infections was 18% (95% CI 10%–28%, predic-
tion interval 2%–64%).
In seven studies, people with SARS-CoV-2 infection were detected through screening of
all people in defined populations who were potentially exposed (303 infected people amongst
10,090 screened) [28,31,34,81,82,93,101]. The screened populations included healthcare workers
[82,93,101]; people evacuated from a setting where SARS-CoV-2 transmission was confirmed,
irrespective of symptom status [28,34]; the whole population of one village in Italy [81]; and blood
donors [31]. In these studies, the summary estimate of the proportion asymptomatic was 31%
(95% CI 26%–37%, prediction interval 24%–38%). There is a risk of selection bias in studies of cer-
tain groups, such as healthcare workers and blood donors, because people with symptoms are
excluded [31,82,93,101], or from nonresponders in population-based screening [81]. Retrospective
symptom ascertainment could also increase the proportion determined asymptomatic [81,82,101].
The remaining studies, in hospital settings, included adult patients only (15 studies,
n = 3,228) [27,39,45,52,53,56,57,64,80,83,89,92,103,107,114], children only (10 studies,
n = 285) [40–42,59,84,87,98,99,104,106], or adults and children (10 studies, n = 1,518)
[54,67,77,79,86,88,96,102,109,112] (Table 1, Fig 1). The types of hospital and clinical severity
of patients differed, including settings in which anyone with SARS-CoV-2 infection was
admitted for isolation and traditional hospitals.
Proportion of presymptomatic SARS-CoV-2 infections
We included 31 studies in which the people with no symptoms of COVID-19 at enrolment
were followed up, and the proportion that develops symptoms is defined as presymptomatic
(Table 2, Fig 2) [21,27,28,31,34,37,38,41,45,46,49,52,55,56,58,67,68,71,73,76,77,79,81,90,93,
95,103,110,111,113,114]. Four studies addressed only this review question [37,38,55,113]. The
findings from the 31 studies were heterogeneous (S4 Fig), even when categorised according to
the method of selection of asymptomatic participants, and we did not estimate a summary
measure (Fig 2).
Additional analyses
We investigated heterogeneity in the estimates of the proportion of asymptomatic SARS-CoV-
2 infections in subgroup analyses that were not specified in the original protocol. In studies of
Table 2. (Continued)
Author Country,
location
Total asymptomatic
SARS-CoV-2, n
Develop symptoms
after testing, n
Sex of asymptomatic
people at time of testing
Age of
asymptomatic people at time
of testing, years, median
Follow-up
methoda
See, KC [41] Malaysia 2 1 0 F, 2 M 5
IQR 1–9
1, 2, 3
Hospitalised adults and children
Kim, SE [77] South Korea 13 3 7 F, 6 M 31
IQR 20.5–51.5
2
Choe, PG [67] South Korea 54 39 32 F, 22 M NR 3
Kong, W [79] China, Sichuan 62 17 NR NR 1
aFollow-up according to protocol (1: 14 days after possible exposure; 2: 7 days after diagnosis; 3: until one or more negative RT-PCR result).
bPeople of different nationalities taken from Diamond Princess cruise ship to a hospital in Japan.
cUntil hospital discharge or negative RT-PCR.
Abbreviations: F, female; IQR, interquartile range; M, male; NR, not reported; RT-PCR, reverse transcriptase PCR; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; USA, United States of America
https://doi.org/10.1371/journal.pmed.1003346.t002
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hospitalised children, the point estimate was higher (27%, 95% CI 22%–32%, 10 studies) than
in adults (11%, 95% CI 6%–19%, 15 studies) (Fig 1). The proportion of asymptomatic SARS--
CoV-2 infection estimated in studies of hospitalised patients (35 studies, 19%, 95% CI 14%–
25%) was similar to that in all other settings (44 studies, 22%, 95% CI 17%–29%, S5 Fig). To
examine publication status, we conducted a sensitivity analysis, omitting studies that were
identified as preprints at the time of data extraction (S6 Fig). The estimate of the proportion of
asymptomatic infection in all settings (18%, 95% CI 14%–22%) and setting-specific estimates
were very similar to the main analysis.
Contribution of asymptomatic and presymptomatic infection to
SARS-CoV-2 to transmission
Five of the studies that conducted detailed contact investigations provided enough data to cal-
culate a secondary attack rate according to the symptom status of the index cases (Fig 3)
[36,65,66,90,111]. The summary risk ratio for asymptomatic compared with symptomatic was
0.35 (95% CI 0.1–1.27) and for presymptomatic compared with symptomatic people was 0.63
(95% CI 0.18–2.26) [66,90]. The risk of bias in ascertainment of contacts was judged to be low
in all studies.
Fig 1. Forest plot of proportion (‘Prop.’) of people with asymptomatic SARS-CoV-2 infection, stratified by
setting. In the setting ’Contact investigations’, in which more than one cluster was reported, clusters are annotated
with ’[cluster]’. The diamond shows the summary estimate and its 95% CI. The red bar and red text show the
prediction interval. CI, confidence interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
https://doi.org/10.1371/journal.pmed.1003346.g001
Fig 2. Forest plot of proportion (‘Prop.’) of people with presymptomatic SARS-CoV-2 infection, stratified by
setting. CI, confidence interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
https://doi.org/10.1371/journal.pmed.1003346.g002
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We included eight mathematical modelling studies (Fig 4) [19,20,33,51,63,69,78,91]. The
models in five studies were informed by analysis of data from contact investigations in China,
South Korea, Singapore, and the Diamond Princess cruise ship, using data to estimate the serial
interval or generation time [19,20,33,69,78], and in three studies the authors used previously
published estimates [51,63,91].
Estimates of the contributions of both asymptomatic and presymptomatic infections
SARS-CoV-2 transmission were very heterogeneous. In two studies, the contributions to
SARS-CoV-2 transmission of asymptomatic infection were estimated to be 6% (95% CrI 0%–
57%) [19] and 69% (95% CrI 20%–85%) [69] (Fig 4). The estimates have large uncertainty
intervals and the disparate predictions result from differences in the proportion of asymptom-
atic infections and relative infectiousness of asymptomatic infection. Ferretti and colleagues
provide an interactive web application [19] that shows how these parameters affect the model
results.
Models of the contribution of presymptomatic transmission used different assumptions
about the durations and distributions of infection parameters such as incubation period,
Fig 3. Forest plot of the RR and 95% CI of the SAR, comparing infections in contacts of asymptomatic and
presymptomatic index cases with infections in contacts of symptomatic cases. The RR is on a logarithmic scale. CI,
confidence interval; E, number of secondary transmission events; N, number of close contacts; RR, risk ratio; SAR,
secondary attack rate.
https://doi.org/10.1371/journal.pmed.1003346.g003
Fig 4. Forest plot of proportion (‘Prop.’) of SARS-CoV-2 infection resulting from asymptomatic or
presymptomatic transmission. For studies that report outcomes in multiple settings, these are annotated in brackets.
CI, confidence interval; GI, generation interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SI,
serial interval.
https://doi.org/10.1371/journal.pmed.1003346.g004
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generation time, and serial interval [19,20,33,51,63,78,91]. In models that accounted for uncer-
tainty appropriately, most estimates of the proportion of transmission resulting from people
with SARS-CoV-2 who are presymptomatic ranged from 20% to 70%. In one study that esti-
mated a contribution of<1% [91], the model-fitted serial interval was longer than observed in
empirical studies [115]. The credibility of most modelling studies was limited by the absence
of external validation. The data to which the models were fitted were generally from small sam-
ples (S7 Fig).
Discussion
Summary of main findings
The summary proportion of SARS-CoV-2 that is asymptomatic throughout the course of infec-
tion was estimated, across all study settings, to be 20% (95% CI 17%–25%, 79 studies), with a pre-
diction interval of 3%–67%. In studies that identified SARS-CoV-2 infection through screening of
defined populations, the proportion of asymptomatic infections was 31% (95% CI 26%–37%, 7
studies). In 31 studies reporting on people who are presymptomatic but who go on to develop
symptoms, the results were too heterogeneous to combine. The secondary attack rate from
asymptomatic infections may be lower than that from symptomatic infections (relative risk 0.35,
95% CI 0.1–1.27). Modelling studies estimated a wide range of the proportion of all SARS-CoV-2
infections that result from transmission from asymptomatic and presymptomatic individuals.
Strengths and weaknesses
A strength of this review is that we used clear definitions and separated review questions to dis-
tinguish between SARS-CoV-2 infections that remain asymptomatic throughout their course
from those that become symptomatic and to separate proportions of people with infection
from their contribution to transmission in a population. This living systematic review uses
methods to minimise bias whilst increasing the speed of the review process [5,6] and will be
updated regularly. We only included studies that provided information about follow-up
through the course of infection, which allowed reliable assessment about the proportion of
asymptomatic people in different settings. In the statistical synthesis of proportions, we used a
method that accounts for the binary nature of the data and avoids the normality approxima-
tion (weighted logistic regression).
Limitations of the review are that most included studies were not designed to estimate the
proportion of asymptomatic SARS-CoV-2 infection and definitions of asymptomatic status
were often incomplete or absent. The risks of bias, particularly those affecting selection of par-
ticipants, differed between studies and could result in both underestimation and overestima-
tion of the true proportion of asymptomatic infections. Also, we did not consider the possible
impact of false negative RT-PCR results, which might be more likely to occur in asymptomatic
infections [116] and would underestimate the proportion of asymptomatic infections [117].
The four databases that we searched are not comprehensive, but they cover the majority of
publications and we do not believe that we have missed studies that would change our
conclusions.
Comparison with other reviews
We found narrative reviews that reported wide ranges (5%–96%) of infections that might be
asymptomatic [1,118]. These reviews presented cross-sectional studies alongside longitudinal
studies and did not distinguish between asymptomatic and presymptomatic infection. We
found three systematic reviews, which reported similar summary estimates from meta-analysis
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of studies published up to May [119–121]. In two reviews, authors applied inclusion criteria to
reduce the risks of selection bias, with summary estimates of 11% (95% CI 4%–18%, 6 studies)
[120] and 15% (95% CI 12%–18%, 9 studies) [121]. Our review includes all these studies,
mostly in the categories of aggregated contact or outbreak investigations, with compatible
summary estimates (Fig 1). We categorised one report [81] with other studies in which a
defined population was screened. The summary estimate in the third systematic review (16%,
95% CI 10%–23%, 41 studies) [119] was similar to that of other systematic reviews, despite
inclusion of studies with no information about follow-up. In comparison with other reviews,
rather than restricting inclusion, we give a comprehensive overview of studies with adequate
follow-up, with assessment of risks of bias and exploration of heterogeneity (S2–S7 Figs). The
three versions of this review to date have shown how types of evidence change over time, from
single-family investigations to large screening studies (S1 Table).
Interpretation
The findings from systematic reviews, including ours [119–121], do not support the claim that
a large majority of SARS-CoV-2 infections are asymptomatic [122]. We estimated that, across
all study settings, the proportion of SARS-CoV-2 infections that are asymptomatic throughout
the course of infection is 20% (95% CI 17%–25%). The wider prediction interval reflects the
heterogeneity between studies and indicates that future studies with similar study designs and
in similar settings will estimate a proportion of asymptomatic infections from 3% to 67%.
Studies that detect SARS-CoV-2 through screening of defined populations irrespective of
infection status at enrolment should be less affected by selection biases. In this group of stud-
ies, the estimated proportion of asymptomatic infection was 31% (95% CI 26%–37%, predic-
tion interval 24%–38%). This estimate suggests that other studies might have had an
overrepresentation of participants diagnosed because of symptoms, but there were also poten-
tial selection biases in screening studies that might have overestimated the proportion of
asymptomatic infections. Our knowledge to date is based on data collected during the acute
phase of an international public health emergency, mostly for other purposes. To estimate the
true proportion of asymptomatic SARS-CoV-2 infections, researchers need to design prospec-
tive longitudinal studies with clear definitions, methods that minimise selection and measure-
ment biases, and transparent reporting. Serological tests, in combination with virological
diagnostic methods, might improve ascertainment of SARS-CoV-2 infection in asymptomatic
populations. Prospective documentation of symptom status would be required, and improve-
ments in the performance of serological tests are still needed [123].
Our review adds to information about the relative contributions of asymptomatic and pre-
symptomatic infection to overall SARS-CoV-2 transmission. Since all people infected with
SARS-CoV-2 are initially asymptomatic, the proportion that will go on to develop symptoms
can be derived by subtraction from the estimated proportion with true asymptomatic infec-
tions; from our review, we would estimate this fraction to be 80% (95% CI 75%–83%). Since
SARS-CoV-2 can be transmitted a few days before the onset of symptoms [124], presymptom-
atic transmission likely contributes substantially to overall SARS-CoV-2 epidemics. The analy-
sis of secondary attack rates provides some evidence of lower infectiousness of people with
asymptomatic than symptomatic infection (Fig 3) [36,65,66,90,111], but more studies are
needed to quantify this association more precisely. If both the proportion and transmissibility
of asymptomatic infection are relatively low, people with asymptomatic SARS-CoV-2 infection
should account for a smaller proportion of overall transmission than presymptomatic individ-
uals. This is consistent with the findings of the only mathematical modelling study in our
review that explored this question [19]. Uncertainties in estimates of the true proportion and
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the relative infectiousness of asymptomatic SARS-Cov-2 infection and other infection parame-
ters contributed to heterogeneous predictions about the proportion of presymptomatic trans-
mission [20,33,51,63,78,91].
Implications and unanswered questions
Integration of evidence from epidemiological, clinical, and laboratory studies will help to clar-
ify the relative infectiousness of asymptomatic SARS-CoV-2. Studies using viral culture as well
as RNA detection are needed, since RT-PCR defined viral loads appear to be broadly similar in
asymptomatic and symptomatic people [116,125]. Age might play a role as children appear
more likely than adults to have an asymptomatic course of infection (Fig 1) [126]; age was
poorly reported in studies included in this review (Table 1).
SARS-CoV-2 transmission from people who are either asymptomatic or presymptomatic
has implications for prevention. Social distancing measures will need to be sustained at some
level because droplet transmission from close contact with people with asymptomatic and pre-
symptomatic infection occurs. Easing of restrictions will, however, only be possible with wide
access to testing, contact tracing, and rapid isolation of infected individuals. Quarantine of
close contacts is also essential to prevent onward transmission during asymptomatic or pre-
symptomatic periods of those that have become infected. Digital, proximity tracing could sup-
plement classical contact tracing to speed up detection of contacts to interrupt transmission
during the presymptomatic phase if shown to be effective [19,127]. The findings of this system-
atic review of publications early in the pandemic suggests that most SARS-CoV-2 infections
are not asymptomatic throughout the course of infection. The contribution of presymptomatic
and asymptomatic infections to overall SARS-CoV-2 transmission means that combination
prevention measures, with enhanced hand and respiratory hygiene, testing tracing, and isola-
tion strategies and social distancing, will continue to be needed.
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